Streetbeat News

CMND

Clearmind Medicine Inc.

https://www.clearmindmedicine.com

Industry

Biotechnology

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Open

1.33

Mkt cap

5.4M

Volume

23K

High

1.34

P/E Ratio

-1.07

52-wk high

6.80

Low

1.32

Div yield

N/A

52-wk low

0.92

UK-based venture studio Beckley Waves has raised $3.3 million in a funding round to expand safe and legal access to psychedelic therapies. The round was oversubscribed by 10% and included participation from several family and VC mission-aligned offices. The funds will be used for strategic investments into selected early-stage teams. In other news, Israeli biotech company Clearmind Medicine (NASDAQ:CMND) is pricing its US-only public offering, expecting to raise approximately $2.25 million. The offering consists of 7.5 million common shares and pre-funded warrants, and 7.5 million common warrants.

Portfolio Pulse from Lara Goldstein

September 15, 2023 | 4:09 pm

U.S. stocks traded higher with the Nasdaq Composite gaining more than 100 points. First Wave BioPharma shares spiked 23% after announcing a license agreement for capeserod from Sanofi. PFSweb shares shot up 48% after GXO Logistics announced it will acquire the company. MYT Netherlands Parent B.V. shares gained 13% after reporting Q4 financial results. IBEX Limited shares dropped 25% after reporting worse-than-expected Q4 results and issuing FY24 revenue guidance below estimates. Clearmind Medicine shares were down 57% after announcing pricing of a public offering. BIOLASE shares fell 38% after announcing pricing of a public offering.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 6:30 pm

Several stocks experienced significant price movements in Wednesday's mid-day session. First Wave BioPharma shares jumped 89.5% after announcing a license agreement for capeserod from Sanofi. PFSweb gained 48.3% following GXO Logistics' acquisition announcement. Taseko Mines, Avalo Therapeutics, NeuBase Therapeutics, MYT Netherlands Parent, Soluna Holdings, Nikola Corporation, Trinseo, Alaunos Therapeutics, Orchestra BioMed Holdings, Eiger BioPharmaceuticals, Uniti Group, Lixiang Education Holding, TransCode Therapeutics, and Novo Integrated Sciences also saw gains. On the other hand, Sezzle, Clearmind Medicine, BIOLASE, OKYO Pharma, IBEX, Bionomics, MicroCloud Hologram, Harpoon Therapeutics, ZyVersa Therapeutics, Super League Enterprise, Axcella Health, BIMI International Medical, Impel Pharmaceuticals, PureCycle Technologies, Ivanhoe Electric, SIMPPLE, Iovance Biotherapeutics, Radiant Logistics, CS Disco, Ambipar Emergency Response, Genius Sports, and Vital Energy saw declines.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 4:58 pm

U.S. stocks traded higher with the Nasdaq Composite gaining around 100 points. Energy shares jumped by 1.2%. First Wave BioPharma, PFSweb, and MYT Netherlands Parent shares rose significantly after positive news. However, IBEX Limited, Clearmind Medicine, and BIOLASE shares dropped due to negative financial results and public offerings. Oil traded up 1.7% to $90.04.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 4:19 pm

Clearmind Medicine Inc (NASDAQ:CMND) announced the pricing of a $2.25 million public offering, causing its shares to drop by 53% to $0.18. The offering is expected to close on September 18. The company plans to use the proceeds for general corporate purposes, including R&D, working capital, future acquisitions, and capital expenditures.

Portfolio Pulse from Henry Khederian

September 14, 2023 | 3:03 pm

Clearmind announced the pricing of a $2.25 million public offering, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 2:24 pm

US stocks traded higher following the release of PPI data, with the Dow, NASDAQ, and S&P 500 all seeing gains. Energy shares jumped by 1.4%, while consumer discretionary shares fell by 0.1%. US producer prices rose by 0.7% in August 2023, higher than the expected 0.4% increase. Shares of First Wave BioPharma, PFSweb, and TradeUP Acquisition Corp. saw significant increases, while shares of Sezzle, Clearmind Medicine, and BIOLASE fell sharply.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 2:03 pm

Clearmind Medicine has announced the pricing of its public offering of 7.5 million shares at $0.30 per share, aiming to raise $2.25 million.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:27 pm

Several stocks experienced significant movement in pre-market trading. TransCode Therapeutics (RNAZ) rose 43.3%, Avalo Therapeutics (AVTX) rose 39.5% after agreeing to divest AVTX-800 series, and Esports Entertainment Group (GMBL) gained 30.1%. Eiger BioPharmaceuticals (EIGR) rose 17.6% despite discontinuing a Phase 3 study. Salem Media Group (SALM) rose 17%, Faraday Future (FFIE) rose 14.7% after delivering a vehicle to a Netflix star, and Novo Integrated Sciences (NVOS) jumped 8.7% after its product was approved by Turkey's Ministry of Health. On the downside, BIOLASE (BIOL) fell 43.3% after announcing a public offering, OKYO Pharma (OKYO) fell 22.7% after announcing a public offering, and IBEX Limited (IBEX) fell 11.1% after reporting downbeat Q4 results and a weak FY24 revenue outlook.

Portfolio Pulse from Lisa Levin

September 14, 2023 | 12:05 pm

The Usona Institute has shared positive results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for adults with Major Depressive Disorder. COMPASS Pathways (NASDAQ:CMPS) has also shared results from research on its novel AI technologies to support proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression. In the UK, drug policy reform is underway, with a report urging the reclassification of psilocybin mushrooms and other psychedelics to Schedule 2. Several US states are also moving reform bills concerning the study or legalization of psychedelic substances for therapeutic purposes. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.79 on September 5, recovering from the prior week’s $1.65.

Portfolio Pulse from Lara Goldstein

September 11, 2023 | 1:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.